Keros Therapeutics (KROS) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Keros Therapeutics (KROS) over the past year, gaining 8.4% versus a loss of 28.4%. Over five years, PLX leads with a +120.3% price change compared with -71.2% for KROS. Keros Therapeutics is the larger company by market cap ($222.3 million vs $218.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | PLX |
|---|---|---|
| Share price | $11.21 | $2.71 |
| Market cap | $222.26M | $218.35M |
| 1-day change | +1.82% | -0.73% |
| YTD return | -44.94% | +50.56% |
| 1-year return | -28.37% | +8.40% |
| 5-year return | -71.25% | +120.33% |
| P/E ratio (TTM) | — | 11.78 |
| Forward P/E | — | 4.37 |
| EPS (TTM) | $-3.22 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $3.19 |
| 52-week low | $9.69 | $1.60 |
| Distance from 52-week high | -50.29% | -15.05% |
| Analyst consensus | buy | none |
| Avg. price target upside | +76.90% | +305.90% |
| Average volume | 197.68K | 731.66K |
| Shares outstanding | 19.83M | 80.57M |
| Employees | 92 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed KROS by 36.8 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
KROS vs PLX FAQ
Which is bigger, Keros Therapeutics or Protalix BioTherapeutics (DE)?
Keros Therapeutics (KROS) is larger, with a market capitalization of $222.26M compared with $218.35M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, KROS or PLX?
PLX returned +8.40% over the past 12 months, compared with -28.37% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Keros Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Protalix BioTherapeutics (DE).